Drug Profile


Alternative Names: MabThera SC; Rituxan Hycela; RITUXAN SC; Rituximab subcutaneous

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Halozyme Therapeutics; Roche
  • Class Antineoplastics; Glycoside hydrolases; Monoclonal antibodies; Polysaccharide lyases
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma

Most Recent Events

  • 23 Jun 2017 Launched for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy, Second-line therapy or greater) in USA (SC)
  • 23 Jun 2017 Launched for Diffuse large B cell lymphoma (First-line therapy, Combination therapy) in USA (SC)
  • 23 Jun 2017 Launched for Follicular lymphoma (First-line therapy, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top